These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 31189746)
1. DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma. Zhou C; Wang P; Tu M; Huang Y; Xiong F; Wu Y Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31189746 [TBL] [Abstract][Full Text] [Related]
2. DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway. Guo W; Li H; Liu H; Ma X; Yang S; Wang Z Oncol Rep; 2019 Sep; 42(3):1075-1089. PubMed ID: 31322256 [TBL] [Abstract][Full Text] [Related]
3. DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis. Qu D; Cui F; Lu D; Yang Y; Xu Y Cancer Sci; 2019 Jan; 110(1):157-165. PubMed ID: 30417471 [TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of AURKA and HSF1 suppresses proliferation and promotes apoptosis in hepatocellular carcinoma by activating endoplasmic reticulum stress. Shen Z; Yin L; Zhou H; Ji X; Jiang C; Zhu X; He X Cell Oncol (Dordr); 2021 Oct; 44(5):1035-1049. PubMed ID: 34176092 [TBL] [Abstract][Full Text] [Related]
5. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1. Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944 [TBL] [Abstract][Full Text] [Related]
6. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056 [TBL] [Abstract][Full Text] [Related]
7. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells. Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525 [TBL] [Abstract][Full Text] [Related]
8. DEP domain containing 1 is a novel diagnostic marker and prognostic predictor for hepatocellular carcinoma. Yuan SG; Liao WJ; Yang JJ; Huang GJ; Huang ZQ Asian Pac J Cancer Prev; 2014; 15(24):10917-22. PubMed ID: 25605201 [TBL] [Abstract][Full Text] [Related]
9. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma. Li H; Liu Y; Jiang W; Xue J; Cheng Y; Wang J; Yang R; Zhang X BMC Cancer; 2021 Mar; 21(1):318. PubMed ID: 33765973 [TBL] [Abstract][Full Text] [Related]
10. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Jin F; Wang Y; Li M; Zhu Y; Liang H; Wang C; Wang F; Zhang CY; Zen K; Li L Cell Death Dis; 2017 Jan; 8(1):e2540. PubMed ID: 28079894 [TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation. Ding H; Liu J; Zou R; Cheng P; Su Y J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375 [TBL] [Abstract][Full Text] [Related]
12. LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway. Xing Y; Liu Y; Qi Z; Liu Z; Wang X; Zhang H Cell Mol Biol Lett; 2021 Nov; 26(1):49. PubMed ID: 34837962 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1. Yang PW; Lu ZY; Pan Q; Chen TT; Feng XJ; Wang SM; Pan YC; Zhu MH; Zhang SH Phytomedicine; 2019 Apr; 57():18-29. PubMed ID: 30668319 [TBL] [Abstract][Full Text] [Related]
14. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-183-5p contributes to malignant progression through targeting PDCD4 in human hepatocellular carcinoma. Duan X; Li W; Hu P; Jiang B; Yang J; Zhou L; Mao X; Tian B Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33078826 [TBL] [Abstract][Full Text] [Related]
16. Mir-452-3p: A Potential Tumor Promoter That Targets the CPEB3/EGFR Axis in Human Hepatocellular Carcinoma. Tang H; Zhang J; Yu Z; Ye L; Li K; Ding F; Feng X; Meng W Technol Cancer Res Treat; 2017 Dec; 16(6):1136-1149. PubMed ID: 29332449 [TBL] [Abstract][Full Text] [Related]
17. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of DEPDC1 Expression in Tumor and Non-tumor Tissue of Patients With Hepatocellular Carcinoma. Amisaki M; Yagyu T; Uchinaka EI; Morimoto M; Hanaki T; Watanabe J; Tokuyasu N; Sakamoto T; Honjo S; Fujiwara Y Anticancer Res; 2019 Aug; 39(8):4423-4430. PubMed ID: 31366540 [TBL] [Abstract][Full Text] [Related]
19. Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice. Xiao CL; Tao ZH; Guo L; Li WW; Wan JL; Sun HC; Wang L; Tang ZY; Fan J; Wu WZ BMC Cancer; 2011 Apr; 11():150. PubMed ID: 21513518 [TBL] [Abstract][Full Text] [Related]
20. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]